presented by mihaela c. badea-mic

31
Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival Alain P. Gobert, David J. McGee, Mahmood Akhtar, George L. Mendz, Jamie C. Newton, Yulan Cheng, Harry L. T. Mobley, and Keith T. Wilson Presented by Mihaela C. Badea-Mic

Upload: pello

Post on 24-Feb-2016

58 views

Category:

Documents


1 download

DESCRIPTION

Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival. Alain P. Gobert, David J. McGee, Mahmood Akhtar, George L. Mendz, Jamie C. Newton, Yulan Cheng, Harry L. T. Mobley, and Keith T. Wilson. Presented by Mihaela C. Badea-Mic. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Presented by Mihaela C. Badea-Mic

Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survivalAlain P. Gobert, David J. McGee, Mahmood Akhtar, George L. Mendz, Jamie C. Newton, Yulan Cheng, Harry  L. T. Mobley,  and Keith T. Wilson

Presented by Mihaela C. Badea-Mic

Page 2: Presented by Mihaela C. Badea-Mic

So, Who Am I?

• Gram negative bacteria inside the stomach and duodenum

The Helicobacter Foundation

Page 3: Presented by Mihaela C. Badea-Mic

Who discovered me?

• 1983-Campylobacter pyloridis

• 1997- Tomb et al sequenced the HP genome

• The Helicobacter Foundation, 2005

Page 4: Presented by Mihaela C. Badea-Mic

Epidemiology• Prevalence (USA)• African-American• Hispanic• Eastern Europeans

• UBIQUITOUS• 50% world population

• The Helicobacter Foundation, 2005

Page 5: Presented by Mihaela C. Badea-Mic

Pathophysiology

• The most common route of H. Pylori infection• Oral to oral• Fecal to oral

PS: watch your pets!

Page 6: Presented by Mihaela C. Badea-Mic

Histology

The Helicobacter Foundation, 2005

Page 7: Presented by Mihaela C. Badea-Mic

Diagnosis

・ Breath test

- Based on the detection of the products of urea

The Helicobacter Foundation, 2005

Page 8: Presented by Mihaela C. Badea-Mic

Diagnosis- cont.

・ Esophagogastroduodenoscopy with biopsy

・ H. Pylori fecal antigen・ H. Pylori serology

Page 9: Presented by Mihaela C. Badea-Mic

Diseases

The Helicobacter Foundation, 2005

Page 10: Presented by Mihaela C. Badea-Mic

Diseases- cont.

• Gastric and duodenal ulcers• Gastric cancer ( 90%)• Non-ulcer dyspepsia• Weird syndromes

Page 11: Presented by Mihaela C. Badea-Mic

Treatment

• Antidiarrheals – bistmuth• Antibiotics - metronidazole, tetracycline,

amoxicilin• Proton pump inhibitors - omeprazole,

lansoprazole• H2 receptor blockers – ranitidine,

famotidine

Page 12: Presented by Mihaela C. Badea-Mic

My survival strategies

D. S. Merrel et al, 2004

Page 13: Presented by Mihaela C. Badea-Mic

My virulence factors

D. M. Monack et al, 2004

Page 14: Presented by Mihaela C. Badea-Mic

Details

D. M. Monack et al, 2004

Page 15: Presented by Mihaela C. Badea-Mic

And now…finally the paper

• Activated macrophages produce NO using L-arginine as a substrate

• H. Pylori arginase competes with NOS2 for the substrate• H. Pylori converts the substrate to urea and L-ornithine,

not NO• rocF gene encodes arginase • Mutations in rocF gene helps the NO to kill H. Pylori

Page 16: Presented by Mihaela C. Badea-Mic

Experiment # 1A

• Hypothesis - the activated macrophage production of NO is inhibited by wt H. Pylori at physiologic L-arginine concentrations

Page 17: Presented by Mihaela C. Badea-Mic

Experiment #1A – cont.

Conclusion:

-only the wt H. Pylori inhibited NO released

- the arginase deficient H. Pylori did not inhibit

Page 18: Presented by Mihaela C. Badea-Mic

Experiment # 1B

• Conclusion: adding more substrate

will stop the competitive inhibition between H. pylori and activated macrophages

Page 19: Presented by Mihaela C. Badea-Mic

Experiment # 2

• Hypothesis – H. Pylori wt compete for the same substrate with activated macrophages. This substrate is L-arginine .

Page 20: Presented by Mihaela C. Badea-Mic

Experiment # 2 –cont.

Conclusion-the wt H. Pylori uses L-arginine decreasing the macrophage NO production because of the loss of the substrate- the rocF mutant does not use the L-arginine

Page 21: Presented by Mihaela C. Badea-Mic

Experiment # 3

• Hypothesis – the macrophage production of NO is regulated by the H. Pylori arginase independently of iNOS expression

• Conclusion- both H. Pylori induce iNOS mRNA expression

Page 22: Presented by Mihaela C. Badea-Mic

Experiment # 4

• Hypothesis – The bacterial arginase inhibits the release of NO by preformed iNOS in macrophages.

Page 23: Presented by Mihaela C. Badea-Mic

Experiment # 4-cont

• Conclusion:the wt H. Pylori inhibits

macrophage NO production by the preactivated cells

Page 24: Presented by Mihaela C. Badea-Mic

Experiment # 5

• Hypothesis – Only viable H.pylori can inhibit the release of macrophage NO

• Conclusion : only live H. Pylori can consume the substrate in order to inhibit the iNOS

Page 25: Presented by Mihaela C. Badea-Mic

Experiment # 6

• Hypothesis – Inhibition of the host cell NO production is a survival strategy for H. Pylori .

• Conclusion – the wt H. Pylori has an increased rate of survival in comparison with rocF mutant H. Pylori in the presence of macrophages .

Page 26: Presented by Mihaela C. Badea-Mic

Experiment # 6 A

Page 27: Presented by Mihaela C. Badea-Mic

Experiment # 6B

Conclusion:The rocF mutant H. Pylori survives in the presence of iNOS -/- macrophages.

Page 28: Presented by Mihaela C. Badea-Mic

Summary

• Bacterial arginase evolutionary adaptation survival strategy for H. pylori gastric mucosa protection

Page 29: Presented by Mihaela C. Badea-Mic

Don’t let your kids kiss us!

The Helicobacter Foundation, 2005

Page 30: Presented by Mihaela C. Badea-Mic

Invitation

Page 31: Presented by Mihaela C. Badea-Mic

That is all I had to say…

• The End!